Altimmune Stock Today
| ALT Stock | USD 7.08 0.49 6.47% |
Performance0 of 100
| Odds Of DistressLess than 46
|
Altimmune is selling for under 7.08 as of the 25th of April 2024; that is -6.47 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 7.08. Altimmune has 46 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Altimmune are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of October 2005 | Category Healthcare | Classification Health Care |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Altimmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 70.9 M outstanding shares of which 17.73 M shares are presently shorted by investors with about 3.42 days to cover. More on Altimmune
Moving against Altimmune Stock
| 0.65 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.54 | ELYM | Eliem Therapeutics | PairCorr |
| 0.53 | CGC | Canopy Growth Corp Trending | PairCorr |
Altimmune Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Altimmune's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Altimmune or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | William Enright | |||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Altran Technologies S.A, Analytica Ltd, Alturas Minerals Corp.] | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Stock Exchange Of, SET Total Return, NASDAQ Composite, NASDAQ Health Care, HNX MidSmall Cap, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Altimmune report their recommendations after researching Altimmune's financial statements, talking to executives and customers, or listening in on Altimmune's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Altimmune. The Altimmune consensus assessment is calculated by taking the average forecast from all of the analysts covering Altimmune. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the measurements of operating efficiency obtained from Altimmune's historical financial statements, Altimmune may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Altimmune is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Altimmune's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Altimmune's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Altimmune's financial leverage. It provides some insight into what part of Altimmune's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Altimmune (ALT) is traded on NASDAQ Exchange in USA. It is located in 910 Clopper Road, Gaithersburg, MD, United States, 20878 and employs 59 people. Altimmune is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 522.5 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Altimmune's market, we take the total number of its shares issued and multiply it by Altimmune's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Altimmune runs under Biotechnology sector within Health Care industry. The entity has 70.9 M outstanding shares of which 17.73 M shares are presently shorted by investors with about 3.42 days to cover.
Altimmune has about 184.76 M in cash with (76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.81.
Check Altimmune Probability Of Bankruptcy
Ownership AllocationAltimmune holds a total of 70.9 Million outstanding shares. Over half of Altimmune's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Altimmune. Please watch out for any change in the institutional holdings of Altimmune as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Altimmune Ownership Details
Altimmune Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Altimmune jumping above the current price in 90 days from now is roughly 96.0%. The Altimmune probability density function shows the probability of Altimmune stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 4.5335. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Altimmune will likely underperform. Additionally, altimmune has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Altimmune to move above the current price in 90 days from now is roughly 96.0 (This Altimmune probability density function shows the probability of Altimmune Stock to fall within a particular range of prices over 90 days) .
Altimmune Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Altimmune that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Altimmune's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Altimmune's value.| Instituion | Recorded On | Shares | |
| Amvescap Plc. | 2023-12-31 | 746.2 K | |
| Susquehanna International Group, Llp | 2023-12-31 | 733.3 K | |
| D. E. Shaw & Co Lp | 2023-09-30 | 730.7 K | |
| Jane Street Group, Llc | 2023-12-31 | 580.4 K | |
| Group One Trading, Lp | 2023-12-31 | 547.4 K | |
| Northern Trust Corp | 2023-12-31 | 473.8 K | |
| Ardsley Advisory Partners | 2023-12-31 | 341 K | |
| Ensign Peak Advisors Inc | 2023-12-31 | 326.8 K | |
| Fred Alger Management, Llc | 2023-12-31 | 326.7 K | |
| Ameriprise Financial Inc | 2023-12-31 | 4.2 M | |
| Blackrock Inc | 2023-12-31 | 4 M |
Altimmune Historical Income Statement
Altimmune Income Statement is one of the three primary financial statements used for reporting Altimmune's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Altimmune revenue and expense. Altimmune Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Altimmune's Other Operating Expenses is comparatively stable compared to the past year. Research Development is likely to gain to about 68.6 M in 2024, whereas Total Revenue is likely to drop slightly above 404.7 K in 2024. View More FundamentalsAltimmune Stock Against Markets
Picking the right benchmark for Altimmune stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Altimmune stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Altimmune is critical whether you are bullish or bearish towards Altimmune at a given time. Please also check how Altimmune's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Altimmune without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sync Your Broker Now
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
| All Next | Launch Module |
Altimmune Corporate Directors
Altimmune corporate directors refer to members of an Altimmune board of directors. The board of directors generally takes responsibility for the Altimmune's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Altimmune's board members must vote for the resolution. The Altimmune board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Maurice Tchenio | Director - Permanent Representative of Apax Partners | Profile | |
| Phuong Thai | Director of Marketing | Profile | |
| Carl Stubbings | Non-Executive Director | Profile | |
| Florence Parly | Independent Director | Profile |
How to buy Altimmune Stock?
Before investing in Altimmune, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Altimmune. To buy Altimmune stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Altimmune. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Altimmune stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Altimmune stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Altimmune stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Altimmune, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.
Already Invested in Altimmune?
The danger of trading Altimmune is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Altimmune is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Altimmune. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Altimmune is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Altimmune is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Altimmune Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Altimmune Stock. Highlighted below are key reports to facilitate an investment decision about Altimmune Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Altimmune Stock analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.66) | Revenue Per Share 0.008 | Quarterly Revenue Growth 180 | Return On Assets (0.25) | Return On Equity (0.47) |
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Altimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.